Sanofi Hampered By Fitusiran Clinical Hold In Hemophilia
Reports Of Non-Fatal Thrombotic Events
Executive Summary
The French major stressed to Scrip that patients enrolled in its fitusiran clinical trials often have other health issues and various co-morbidities, so it is too early to know if the adverse events are treatment-related.
You may also be interested in...
Fitusiran Delay Dents Sanofi’s Hemophilia Challenge
New data show fitusiran’s promise across hemophilia A and B, but a switch to a lower dose prompted by safety concerns will delay its filing until 2024.
Five Hematology Drug Launches To Look Out For In 2022
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are five new hematology products that could make their market debuts (or return) next year.
Sanofi Spotlights Nirsevimab In RSV, Further Dupixent Development
Sanofi executives are upbeat about the potential advantages of its monoclonal antibody-based approach to the prevention of RSV infections in infants, the future growth of the company’s Dupixent franchise, and the progress of its novel anticancers.